[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568653":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":45,"collaborators":19,"id":48,"slug":19,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":19,"eligibilityCriteria":52,"healthyVolunteers":49,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":19,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Affiliated Hospital of Jiangnan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-FAPI-JNU","EXPERIMENTAL","68Ga-FAPI-JNU is administered through a superficial vein on the back of the hand. A PET\u002FCT scan was performed approximately 1 hour after injection",[13],"Drug: 68Ga-FAPI-JNU",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Patients will receive the novel tracer 68Ga-FAPI-JNU dose of approximately 2-5 mCi per person",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"chunjing Yu","CONTACT","15312238622","ycj_wxd1978@163.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Affiated Hospital of Jiangnan University","RECRUITING","Wuxi","Jiangsu","214000","China","CN",{"type":36,"coordinates":37},"Point",[38,39],120.28857,31.56887,{"lat":39,"lon":38},[42],{"name":43,"role":23,"phone":24,"phoneExt":19,"email":44},"Chunjing Yu","ycjwxd1978@jiangnan.edu.cn",{"type":46,"investigatorFullName":43,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Director","100568653",false,"NCT06684028","PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors","Inclusion Criteria:\n\n1. The subjects sign the informed consent voluntarily and can complete the test according to the protocol requirements;\n2. Age 18-85 years old, male or female;\n3. Clinically diagnosed as malignant tumor, diagnostic criteria refer to biopsy or other imaging such as CT and MRI;\n4. ECOG score is 0-3 points;\n\nExclusion Criteria:\n\n1. Patients with a history or allergic constitution to any component of the developer, including alcohol;\n2. pregnant or lactating women;\n3. Patients with mental illness or related history;\n4. Patients who cannot or cannot undergo a PET\u002FCT scan;","ALL","18 Years","85 Years",{"count":57,"type":58},30,"ESTIMATED","INTERVENTIONAL",[61],"NA","To investigate the biological distribution of a new tracer 68Ga-FAPI-JNU in the primary, metastatic and normal tissues of patients with malignant tumors, and to evaluate the biological distribution of 68GA-FAPI-JNU with standardized uptake values.",[64,65],"Cancer","Solid Malignancies",[67,68,69,70],"FAP","FAPI","PET","cancer","2025-01-18",{"date":73,"type":74},"2025-01-22","ACTUAL",{"date":76,"type":74},"2023-07-12",{"date":78,"type":58},"2025-07-31",{"name":5,"class":6},1]